0001628280-18-003310.txt : 20180316 0001628280-18-003310.hdr.sgml : 20180316 20180316163719 ACCESSION NUMBER: 0001628280-18-003310 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180313 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20180316 DATE AS OF CHANGE: 20180316 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Menlo Therapeutics Inc. CENTRAL INDEX KEY: 0001566044 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 453757789 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38356 FILM NUMBER: 18696109 BUSINESS ADDRESS: STREET 1: 200 CARDINAL WAY, 2ND FLOOR CITY: REDWOOD CITY STATE: CA ZIP: 94063 BUSINESS PHONE: 650-486-1416 MAIL ADDRESS: STREET 1: 200 CARDINAL WAY, 2ND FLOOR CITY: REDWOOD CITY STATE: CA ZIP: 94063 FORMER COMPANY: FORMER CONFORMED NAME: Menlo Therapeutics, Inc. DATE OF NAME CHANGE: 20170728 FORMER COMPANY: FORMER CONFORMED NAME: Tigercat Pharma, Inc. DATE OF NAME CHANGE: 20130104 8-K 1 palo_alto-mnlox8xkincrease.htm 8-K Document

 
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 
 
 

FORM 8-K

 
 
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
March 13, 2018
 
 
 

Menlo Therapeutics Inc.
(Exact name of registrant as specified in its charter)
 
 
 
 
 
 
 
Delaware
001-38356
45-3757789
(State or other jurisdiction of
incorporation)
(Commission File Number)
(I. R. S. Employer
Identification No.)
200 Cardinal Way, 2nd Floor
Redwood City, California 94063
(Address of principal executive offices, including ZIP code)
(650) 486-1416
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)

 
 
 



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x
 
 

 
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 13, 2018, the Compensation Committee of the Board of Directors (the “Compensation Committee”) of Menlo Therapeutics Inc. (the “Company”) approved the following base salaries for the Company’s executive officers, effective January 1, 2018.

Name
Title
 
 
Base Salary
($)
Steven Basta

President & Chief Executive
Officer
 
580,000
Kristine Ball

Senior Vice President, Corporate Strategy and Chief Financial Officer
 
400,000
Paul Kwon, M.D.

Chief Medical Officer
 
400,000

In addition, the Compensation Committee approved of the annual perform bonus program targets for Mr. Basta, Ms. Ball and Dr. Kwon. Mr. Basta’s target bonus is 55% of his annual base salary. Ms. Ball’s and Dr. Kwon’s target bonus is 40% of their annual base salary.



 
 
 

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
 
Date: March 16, 2018
 
Menlo Therapeutics Inc.
 
 
 
 
 
/s/Steven Basta
 
 
Steven Basta
 
 
President and Chief Executive Officer